Please login to the form below
lurasidone
This page shows the latest lurasidone news and features for those working in and with pharma, biotech and healthcare.
EU approval for Takeda’s schizophrenia drug
Takeda and development partner Dainippon Sumitomo Pharma have won European approval for their schizophrenia treatment Latuda (lurasidone).
Latest news
-
GSK's diabetes drug among CHMP recommendations
2013. Takeda's antipsychotic and Linepharma's Hemoprostol. Elsewhere in the CHMP opinions, Takeda received a recommendation for the use of Latuda (lurasidone) in the treatment of adults with schizophrenia.
-
Schizophrenia treatments
Lurasidone, an antagonist of dopamine D2, serotonin 2A, serotonin 7, serotonin 2C and a partial agonist of serotonin 1A, is being marketed by Sunovion Pharmaceuticals.
-
Coronary conundrums
US. Lurasidone. Latuda (Sunovion Pharmaceuticals). Schizophrenia. US an Puerto Rico. Paracetamol.
-
DSP buys Sepracor
The move comes as DSP prepares to launch its schizophrenia drug lurasidone, which last month significantly outperformed placebo in late-stage trials. ... The acquisition gives DSP the sales and marketing infrastructure in the US it needs to commercialise
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Interview: Trevor Smith, Takeda
There's prostate cancer drug orteronel (TAK-700) and vedolizumab for Crohn's disease and ulcerative colitis, and then the atypical antipsychotic lurasidone. ... From among its product pipeline Smith picks prostate cancer drug orteronel (TAK-700),
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Content Editor - Biotechnology
-
Salary TBC
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
-
Account Management
-
Competitive Salary Offered
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- AZ showcases data for next-generation PARP inhibitor AZD5305
- Sanofi pays $160m upfront to acquire Tidal Therapeutics
- GSK discontinues two feladilimab trials in head and neck cancer
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Pfizer/BioNTech say their COVID-19 vaccine can be stored at warmer temperatures
- FDA approves new self-injection administration for Xolair
- Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- Alexion and NICE agree confidential discount for Ultomiris use on the NHS
- Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses
- Merck & Co halts development of potential COVID-19 drug MK-7110
- Virtually, the same: Is it time to rethink congress strategy?
PMHub
certain health
Transforming the way health brands and companies communicate, we deliver creative science led, insight-driven solutions that give award winning results...
Latest intelligence
- InSite Events™ National Pharma Meeting: A Customer Story
- How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
- Fear or encouragement, which is best to drive behaviour change?
- The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
- The unheard, unseen, and uncorrected effects of COVID-19
- The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...
Quick links
Infographics
